Founded in 1993 as a spin-off of Paris Sorbonne (formerly Pierre and Marie Curie University), our ambition is to develop our Kinoid products, resulting from patented technologies, and to invest in innovative companies such as Biotech and Medtech.
At research and development, our activities revolve around the Kinoid technological platform in two main therapeutic indications, lupus disease and allergies. This innovative approach allows the patient's immune system to regulate the harmful overproduction of cytokines (active immunotherapy). Neovacs'Kinoid technology, used in particular in the treatment of lupus disease, is patented until 2040.
Our investment activity leverages the skills of our experienced scientific and financial teams to invest in promising projects, both in the development of drug candidates (BioTech) and medical devices (MedTech).
3-5 Impasse Reille, 75014 Paris – France
Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.